Edition:
United States

Trovagene Inc (TROV.OQ)

TROV.OQ on NASDAQ Stock Exchange Capital Market

0.67USD
4:00pm EDT
Change (% chg)

$-0.03 (-4.29%)
Prev Close
$0.70
Open
$0.73
Day's High
$0.73
Day's Low
$0.66
Volume
31,218
Avg. Vol
135,750
52-wk High
$4.90
52-wk Low
$0.62

Chart for

About

Trovagene, Inc. (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform... (more)

Overall

Beta: 0.26
Market Cap(Mil.): $26.09
Shares Outstanding(Mil.): 37.27
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.36 16.18
EPS (TTM): -- -- --
ROI: -- 13.79 14.60
ROE: -- 16.62 13.87

BRIEF-Trovagene reports positive data from a preclinical in-vivo study examining combination of their plk1 inhibitor with investigational flt3 inhibitor

* Trovagene's plk1 inhibitor pcm-075, in preclinical aml data, significantly enhances the efficacy of a flt3 inhibitor in combination therapy

Aug 16 2017

BRIEF-Trovagene Q2 loss per share $0.26

* Trovagene announces second quarter 2017 company highlights and financial results

Aug 09 2017

BRIEF-Trovagene, Antonius Schuh and Stephen Zaniboni resolve employment dispute

* Trovagene, Antonius Schuh and Stephen Zaniboni resolve employment dispute

Jul 28 2017

BRIEF-Trovagene announces peer-reviewed publication of first-in-human phase 1 trial results with PCM-075

* Trovagene announces peer-reviewed publication of first-in-human phase 1 trial results with pcm-075, its polo-like kinase 1 (plk1) inhibitor

Jul 25 2017

BRIEF-CVI Investments Inc reports 5.7 percent passive stake in Trovagene as of July 13 - SEC filing

July 24 CVI Investments Inc. Reports 5.7 Pct Passive Stake In Trovagene Inc

Jul 24 2017

BRIEF-Sabby Management reports 5.70 percent passive stake in Trovagene

* Sabby Management LLC reports 5.70 percent passive stake in Trovagene Inc as of July 13 - sec filing Source text : http://bit.ly/2uwdR7Z Further company coverage:

Jul 17 2017

BRIEF-Trovagene announces $7.1 million registered direct offering

* Trovagene announces $7.1 million registered direct offering

Jul 14 2017

BRIEF-Trovagene announces agreement with Novogene

* Trovagene announces agreement with Novogene for NextCollect in China

Jul 12 2017

BRIEF-Trovagene regains compliance with NASDAQ listing requirements

* Trovagene Inc regains compliance with NASDAQ listing requirements Source text for Eikon: Further company coverage:

Jul 10 2017

BRIEF-Trovagene engages PRA Health Sciences to conduct phase 1b/2 trial of PCM-075

* Trovagene engages leading cro in aml to conduct phase 1b/2 trial of pcm-075 Source text for Eikon: Further company coverage:

Jul 06 2017

Earnings vs. Estimates